Huize Partners with PICC Life Insurance to Launch “i Wu You – Low-Threshold Edition” – A Customized Critical Illness Insurance Product
April 19, 2024 07:30 ET
|
Huize Holding Limited
SHENZHEN, China, April 19, 2024 (GLOBE NEWSWIRE) -- Huize Holding Limited, (“Huize”, the “Company” or “we”) (NASDAQ: HUIZ), a leading insurance technology platform connecting consumers, insurance...
Webuy Announces Filing of 2023 Annual Report with the SEC, Launches Travel Business in Indonesia, and Expands into Insurance Referral Program
April 19, 2024 07:30 ET
|
Webuy Global Limited
Singapore, April 19, 2024 (GLOBE NEWSWIRE) -- Webuy Global Ltd (NASDAQ: WBUY) ("Webuy" or the "Company"), a Southeast Asian community e-commerce retailer, today announces that on April 15, 2024, the...
Perella Weinberg to Announce First Quarter 2024 Financial Results and to Host Conference Call on May 3, 2024
April 19, 2024 07:28 ET
|
Perella Weinberg Partners Group LP
NEW YORK, April 19, 2024 (GLOBE NEWSWIRE) -- Perella Weinberg Partners (“PWP”) (NASDAQ:PWP), a leading global independent advisory firm, today announced that it plans to release its financial...
Ocugen Announces Dosing Completion of Subjects with Geographic Atrophy in Cohort 2 of Phase 1/2 ArMaDa Clinical Trial of OCU410—A Modifier Gene Therapy
April 19, 2024 07:13 ET
|
Ocugen
MALVERN, Pa., April 19, 2024 (GLOBE NEWSWIRE) -- Ocugen, Inc. (“Ocugen” or the “Company”) (NASDAQ: OCGN), a biotechnology company focused on discovering, developing, and commercializing novel gene...
Huize Holding Limited Files 2023 Annual Report on Form 20-F
April 19, 2024 07:11 ET
|
Huize Holding Limited
SHENZHEN, China, April 19, 2024 (GLOBE NEWSWIRE) -- Huize Holding Limited, (“Huize,” the “Company” or “we”) (NASDAQ: HUIZ), a leading insurance technology platform connecting consumers, insurance...
ProQR Achieves Successful Defense of New Challenge to its Axiomer™ IP Portfolio
April 19, 2024 07:00 ET
|
ProQR Therapeutics N.V.
LEIDEN, Netherlands & CAMBRIDGE, Mass., April 19, 2024 (GLOBE NEWSWIRE) -- ProQR Therapeutics N.V. (Nasdaq: PRQR) (ProQR), a company dedicated to changing lives through transformative RNA...
Tiziana Life Sciences Announces Study Results from Intranasal Anti-CD3 Foralumab in Multiple Sclerosis Patients with PIRA Highlighted in Neurology Today®
April 19, 2024 07:00 ET
|
Tiziana Life Sciences Ltd.
- Intranasal foralumab attenuated microglial activation in patients with non-active secondary progressive multiple sclerosis and progression independent of relapse (PIRA) -- Data presented in a...
Balchem Corporation Announces Quarterly Conference Call for First Quarter Financial Results on May 3, 2024
April 19, 2024 07:00 ET
|
Balchem Corporation
MONTVALE, N.J., April 19, 2024 (GLOBE NEWSWIRE) -- Balchem Corporation (NASDAQ: BCPC) today announced that a conference call will be held on Friday, May 3, 2024, at 11:00 AM Eastern Time (ET) to...
Alvotech gerir sölusamning í Bandaríkjunum um fyrstu líftæknilyfjahliðstæðuna í háum styrk með útskiptanleika við Humira
April 19, 2024 06:10 ET
|
Alvotech
Langtímasamningur hefur náðst við leiðandi innkaupaaðila lyfja í Bandaríkjunum um sölu- og dreifingu á líftæknilyfjahliðstæðu Alvotech í háum styrk með útskiptanleika við HumiraMeð þessum samningi...
Alvotech signs U.S. agreement to expand access for newly approved high-concentration interchangeable biosimilar to Humira® (adalimumab)
April 19, 2024 06:10 ET
|
Alvotech
Alvotech, in agreement with Teva Pharmaceuticals, has signed an agreement with a strategic partner to bring to the U.S. market the newly FDA approved high-concentration interchangeable biosimilar to...